← Back to Clinical Trials
Recruiting NCT05061680

NCT05061680 Quick Large Balloon Dilatation for Removal of Large Bile Duct Stones (SHODBADI)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05061680
Status Recruiting
Phase
Sponsor Helsinki University Central Hospital
Condition Pancreatitis, Acute
Study Type INTERVENTIONAL
Enrollment 600 participants
Start Date 2021-04-05
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 95 Years
Study Type INTERVENTIONAL
Interventions
endoscopic short duration papillary large balloon dilation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 600 participants in total. It began in 2021-04-05 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

ESGE guidelines suggests 30-60 seconds endoscopic large balloon papillary dilation from the disappearance of the waist of the papilla. The investigators have good results in stone removal with much quicker dilatations when the cholangiogram is followed and the dilation is finished as soon as the disappearance of the waist of the papilla is seen. This Scandinavian multicenter prospective study is especially interested in stone clearance rate and short and long-term adverse events such as pancreatitis, cholangitis, bleeding, perforations, residual biliary stones, and newly developing biliary stones.

Eligibility Criteria

Inclusion Criteria: * Age \>18 years * Common bile duct stone \>10mm diameter Exclusion Criteria: * Altered anatomy after surgery (B II, Roux-en-Y reconstruction) * Common bile duct cysts * Acute pancreatitis * Distal common bile duct stricture or tumor * Coagulation disorders * Ongoing coagulation medication * Pregnancy * Inability to give an informed consent

Contact & Investigator

Central Contact

Mia Rainio, MD, PhD

✉ mia.rainio@hus.fi

📞 +358505833060

Principal Investigator

Mia Rainio, Md, PhD

STUDY DIRECTOR

Helsinki University Central Hospital

Frequently Asked Questions

Who can join the NCT05061680 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 95 Years, studying Pancreatitis, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05061680 currently recruiting?

Yes, NCT05061680 is actively recruiting participants. Contact the research team at mia.rainio@hus.fi for enrollment information.

Where is the NCT05061680 trial being conducted?

This trial is being conducted at Helsinki, Finland, Turku, Finland.

Who is sponsoring the NCT05061680 clinical trial?

NCT05061680 is sponsored by Helsinki University Central Hospital. The principal investigator is Mia Rainio, Md, PhD at Helsinki University Central Hospital. The trial plans to enroll 600 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology